314130.KQ Genome & Company
- Market cap
- KRW 158B
- P/E
- -
- P/B
- 2.36x
- ROE
- -134.6%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 314130.KQ undervalued?
Graham numberThe Graham number of Genome & Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genome & Company fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-134.6%), below 10%.
ROA 0/1
Return on assets (-78.8%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (71.6%) is above the industry median (4.8%).
Revenue Growth 2/2
Revenue grew 20.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.4x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genome & Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs wit…
Full company profileGenome & Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genome & Company annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 451M | 14.1B | 14.3B | 27.7B | 24.6B | 24.1B |
| Gross Profit | 374M | 5.60B | 4.06B | 15.7B | 13.4B | 13.9B |
| Operating Income | -36.1B | -57.5B | -57.4B | -32.6B | -29.2B | -28.1B |
| EBITDA | - | -48.4B | -41.8B | -17.2B | 2.72B | -90.2B |
| Net Income | -34.1B | -51.8B | -47.5B | -20.1B | -6.43B | -96.9B |
| EPS | -1,213 | -1,839 | -1,612 | -648 | -184 | -2,696 |
| Balance Sheet | ||||||
| Total Assets | 137B | 173B | 162B | 147B | 145B | 123B |
| Total Liabilities | 23.8B | 75.7B | 99.6B | 99.0B | 30.4B | 41.7B |
| Shareholders' Equity | 92.7B | 97.3B | 62.4B | 48.3B | 106B | 72.0B |
| Cash & Short-term Investments | 36.0B | 101B | 82.4B | 77.2B | 15.6B | 49.9B |
| Cash Flow | ||||||
| Operating Cash Flow | -26.2B | -36.0B | -31.0B | -7.61B | -18.4B | -13.8B |
| Capital Expenditure | 3.38B | 7.28B | 19.0B | 4.19B | 498M | 851M |
| Free Cash Flow | -29.5B | -50.8B | -51.3B | -20.5B | -18.9B | -14.6B |
| Ratios | ||||||
| ROE | -36.8% | -53.3% | -76.0% | -41.6% | -6.1% | -134.6% |
| ROA | -24.9% | -30.0% | -29.3% | -13.7% | -4.4% | -78.8% |
| Net Profit Margin | -7,560.6% | -368.0% | -332.0% | -72.5% | -26.1% | -402.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genome & Company dividends
Genome & Company has not paid dividends in the last 5 fiscal years.
Last stock split: 2:1 on Aug 6, 2024.
Who owns Genome & Company
- Insiders 14.33%
- Institutions 5.66%
- Public & others 80.01%
- Shares outstanding 45.2M
- Free float 33.6M
Genome & Company company profile
- Company name
- Genome & Company
- Ticker
- 314130.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 96
- Fiscal year end
- December
- Address
- 7th and 8th floors, Suwon-si, South Korea
- Phone
- 82 31 628 0150
- Website
- genomecom.co.kr
About Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.
Genome & Company management
7- Mr. Yoo Seok HongCo-Chief Executive Officer & Director · born 1964
- Mr. Jisoo Pae M.D.Founder, Co-CEO & Representative Director · born 1971
- Mr. Han-Su ParkFounder, Co-CEO, CTO & Representative Director · born 1973
- Jae-wook JungCFO & Internal Accounting Manager
- Gyeong-yeong MinHead of Accounting
- Ms. Hyun-kyung YooMD and Head of Pharmacology & Toxicology Research Lab · born 1974
- Ms. Jin-kyung SeoMD & Head of Consumer Business Group · born 1979